Send to a Friend Share

UBS Reiterates a 'Buy' on Lorillard (LO); Raising Estimates & PT After Strong Qtr

February 10, 2012 12:48 PM EST
LO Hot Sheet
Rating Summary:
    3 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 7 | New: 26
UBS reiterates a 'Buy' on Lorillard (NYSE: LO) price target raised from $124 to $140.

UBS analyst says, "Fundamental Buy Thesis is On Target: We continue to believe there is more upside to Lorillard's EPS (via its more aggressive Newport expansion initiative). And while we continue to recommend investors own LO shares, we caution that trading could be choppy in the near-term (as FDA headlines still loom)."

"We are raising our FY 2012 EPS estimate from $8.62 to $8.94 (consensus $8.54—but likely to move up as well), partly driven by today’s beat, but also due to higher buy back assumptions and slightly higher volume growth."

For an analyst ratings summary and ratings history on Lorillard click here. For more ratings news on Lorillard click here.

Shares of Lorillard closed at $124.37 yesterday, with a 52 week range of $75.77-$127.68.


Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA

Related Entities

UBS

Add Your Comment





Follow StreetInsider.com On Twitter